BTIG halved its price target for TransEnterix (NASDAQ:TRXC) to $1.50 from $3 after the company’s second quarter results fell short of guidance and consensus estimates. The stock closed at $1.15 on Aug. 7. TransEnterix...
By Len Zehr TransEnterix (NYSE MKT:TRXC) plans to file for FDA approval in mid-year of its SurgiBot robotic platform to enhance minimally invasive laparoscopic surgery through a single surgical incision. “We anticipate...